NCT06963060View on ClinicalTrials.gov

Gem+Nab-P+LEN+TIS for Advanced Unresectable BTC (GALENT-BT)

PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
Gallbladder CancerCholangiocarcinoma
Interventions
DRUG

Gemcitabine nab-PaclitaxelLenvatinibTislelizumab

"Receive Gemcitabine (1000 mg/m² IV on Days 1 and 8) and nab-Paclitaxel (125 mg/m² IV on Days 1 and 8) every 3 weeks.~Take Lenvatinib (4-8 mg orally daily on Days 1-21).~Receive Tislelizumab (200 mg IV on Day 1) every 3 weeks."

Trial Locations (1)

200092

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai

All Listed Sponsors
lead

Wei Gong

OTHER